News

The cancer-research community has long recognized lysophosphatidic acid (LPA) as a significant contributor to cancer through its promotion of cancer-cell growth and metastasis in a broad range of

In the collaboration, researchers from the company and the University’s Southwestern Medical Center will evaluate the use of RNAi therapeutics directed to a disease target called proprotein convertase

Alnylam and Inex formed the collaboration in March 2006. The results to date encourage both parties to believe that Alnylam’s RNAi therapeutics can be efficiently encapsulated in Inex’s

As a result of the successful study in the animal model, DNAPrint has selected PT-502 as its lead compound for development. PT-502 uses the dopamine system in order

In Celera’s research studies, two single nucleotide polymorphisms (SNPs) were identified in the DAPK1 (death-associated protein kinase 1) gene that showed significant association with late-onset Alzheimer’s disease. In

The milestone was related to progress in the preclinical development of MEM 63908, the second named development candidate in the company’s nicotinic alpha-7 agonist program. A number of

In December 2005, Wyeth and Progenics Pharmaceuticals entered into a collaboration agreement to develop and commercialize methylnaltrexone. The FDA fast track designation facilitates development and expedites regulatory review

The study, known as EVOLVE, is a clinical outcomes study designed to determine whether Sensipar (cinacalcet HCl), marketed as Mimpara in Europe, can effectively reduce the risk of

The 10-patient study, using a currently marketed drug of approximately 4,000 Daltons in size, revealed an average systemic bioavailability of approximately 35% for the Intravail formulation compared to